Monday, November 14, 2016
- 9:00AM-11:00AM
-
Abstract Number: 1680
Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1711
Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1732
Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1355
ASAH1 Gene Mutations Cause Acid Ceramidase Deficiency (Farber Disease), with Symptoms Including Arthritis and Subcutaneous Nodules. Patients Are Often Misdiagnosed with JIA, and Slowly Progressive Disease May Only be Diagnosed in Adulthood
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1238
Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Health Services Research - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1582
Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1663
Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis
Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I- 9:00AM-11:00AM
-
Abstract Number: 1556
Assessment of the Burden of Comorbidities By the Rheumatic Disease Comorbidity Index in Early Rheumatoid Arthritis Patients at Disease Onset
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1534
Assessment of the Relationship of the Static and Dynamic Balance Parameters with Clinical, Functional and Radiological Findings in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1727
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1686
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1757
Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1260
Association of Traditional Chinese Medicine Use and Adherence to Prescribed Western Medications in Chinese-American Rheumatology Patients
Healthcare Disparities in Rheumatology - Poster II